Helen Kim

Helen S. Kim sits as a member of Aktis Oncology’s Board of Directors. Helen is a Senior Managing Director of Vida Ventures, a life science-focused venture capital firm and currently serves on the Board of Directors for Applied Molecular Transport, PACT Pharma, ReCode, A2 Bio, and Iconovir. She is a Board Observer for Locana Bio and Innoskel. She has more than 30 years of leadership experience in biotechnology, including positions as a Partner at The Column Group and as the Executive Vice President of Business Development at Kite Pharma, Inc. where she successfully led the business and corporate development initiatives resulting in Kite’s acquisition by Gilead in 2017.

Previously, Helen served as Strategic Advisor of NGM Biopharmaceuticals, Inc., Chief Business Officer at NGM Biopharmaceuticals, Inc., and Chief Executive Officer and President of Kosan Biosciences. Her additional industry experience includes executive positions at Affymax, Onyx Pharmaceuticals and Chiron Corporation. She received an MBA from the University of Chicago.